Tag: United States

Former Tech Entrepreneur Brings Global Bubble Tea Brand to Growing Las Vegas MarketLAS VEGAS, June 16, 2026 /PRNewswire/ -- Chatime, one of the world's largest...

A new professional sports league built around authentic competition, global athletes and recurring live eventsSumo Championship League (SCL) will launch live professional league events...

HILLSBOROUGH, N.C., June 16, 2026 /PRNewswire/ -- In honor of National Sex Education Month and as part of its expanding commitment to sexual health...

AmpliTech Group Strengthens ORAN 5G Growth Strategy with Addition of Two Senior Business Development Leaders

EPA Water Finance Clearinghouse adds EPHI's Lead Service Line Replacement Cost Calculator, a free multilingual tool supporting LCRI implementation.

Miami, Florida, June 16, 2026 (GLOBE NEWSWIRE) --

There is a quiet conversation happening in fitting rooms, group texts, and medical offices all over the country that rarely surfaces publicly. It is about arms. More specifically, it is about the moment a woman picks up a sleeveless top, holds it against herself in the mirror, and puts it back on the rack. Not because the top is the wrong color or cut. Because she does not want her arms on display.

Complementary upstream and downstream capabilities to enhance integration and enable the combined company to better create value across cycles, products and regions $400+ million...

PARIS, June 16, 2026 /PRNewswire/ -- In 2025, the global recorded music market reached $31.7 billion (IFPI), with streaming accounting for 69.6% and driving...

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

MUMBAI, India, June 16, 2026 /PRNewswire/ -- InCred Capital, the institutional, wealth and asset management arm of InCred Group, today announced the launch of...

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.